

Ref. No.: CIAN/BSE/2025-26/25

Saturday, March 21, 2026

To,  
The Manager-Listing,  
**BSE Limited**  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai-400 001

**BSE Scrip Code: 542678**

**Trading Symbol: CHCL**

- Subject:**
- i. Disclosure made pursuant to Regulation 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations") by Cian Healthcare Limited ("Company"); and
  - ii. Update on the receipt of the listing approval from the BSE Limited ("Stock Exchange" or "BSE") for the listing of 2,37,50,000 (Two Crores Thirty-Seven Lakhs Fifty Thousand) fully paid-up equity shares at a face value of INR 10/- (Indian Rupees Ten Only) each, aggregating to INR 23,75,00,000 (Indian Rupees Twenty-Three Crores Seventy-Five Lakhs Only) to the promoters on a preferential basis, pursuant to the approved Resolution Plan read with the Order of the Hon'ble National Company Law Tribunal ("NCLT") dated December 18, 2025 ("NCLT Order").

**Reference:** Disclosure dated December 19, 2025, in relation to the approval of the Resolution Plan by the Hon'ble National Company Law Tribunal, Bench-VI, Mumbai ("NCLT") vide its order dated December 18, 2025 ("NCLT Order"), as submitted by the Successful Resolution Applicant ("SRA"), namely Mr. Pradeep Kumar Jain, under the relevant provisions of the Insolvency and Bankruptcy Code, 2016 ("Code").

Dear Sir/Ma'am,

In compliance with the relevant provisions of Regulation 30 read with Schedule III, and other applicable provisions of the Listing Regulations, along with the provisions of SEBI Master Circular No. HO/49/14/14(7)2025-CFDPOD2/1/3762/2026 dated January 30, 2026 ("**SEBI Circular**"), and in accordance with the relevant provisions of the NCLT Order read with the Resolution Plan approved therein and such other applicable laws and regulations, and with reference to the captioned subject, the Company hereby inform the receipt of the listing approval in respect of 2,37,50,000 (Two Crores Thirty-Seven Lakhs Fifty Thousand) fully paid-up equity shares at a face value of INR 10/- (Indian Rupees Ten Only) each, aggregating to INR 23,75,00,000 (Indian Rupees Twenty-Three Crores Seventy-Five Lakhs Only) to the promoters on a preferential basis, the details of which are enumerated hereunder:

**Registered Office:**

Office No.: 301, 3<sup>rd</sup> Floor, Konark Icon, Mundhwa-Kharadi Road,  
Kirtane Baugh, Magarpatta, Hadapsar, Pune, Maharashtra, Pincod-411028.  
Email: enquiry@cian.co  
Mobile No.: +919049000648 Website: [www.cian.co](http://www.cian.co)

**Corporate Office:**

606, Ring Road Mall, Sector-3, Rohini, New Delhi, Pincod-110085.  
Landline No.: 011-49120841

**Factory:** Khasra No.: 245 & 248, Village Sisona, Bhagwanpur,  
Roorkee, District Haridwar, Uttarakhand, Pincod-247661.  
Mobile No.: +917830655000

**CIN:** L24233PN2003PLC017563

S. No.	Name of the Promoters	Total No. of shares	Shareholding Percentage (%)
1.	Ananta Medicare Limited	1,37,50,000	55
2.	Mr. Rajesh Jain	52,50,000	21
3.	Mr. Pradeep Kumar Jain	47,50,000	19
<b>Total</b>		<b>2,37,50,000</b>	<b>95</b>

The Company shall proceed with the completion of the requisite trading formalities in respect of the aforesaid equity shares and take necessary steps for crediting the shares to the demat accounts of the respective shareholders, in accordance with the conditions specified in the listing approval letter and other applicable statutory and regulatory requirements.

A copy of the listing approval letter received from BSE is attached herewith as **Annexure-A**.

We shall continue to keep all stakeholders and regulatory authorities abreast of further material developments in this regard.

Kindly take the above information on record and oblige.

Thanking you,  
**For Cian Healthcare Limited**

-----  
**Rachit Malhotra**  
**Company Secretary and Chief Compliance Officer**  
**Membership No. A39894**

**Place: Delhi**



LOD/PREF/TS/FIP/4134/2025-26

March 20, 2026

To,  
The Company Secretary,  
**Cian Healthcare Ltd**  
606, 6<sup>th</sup> Floor, Ring Road Mall,  
Sector-3, Rohini, New Delhi – 110085.

**Subject: Listing of 2,37,50,000 equity shares of Rs. 10/- each bearing distinctive numbers from 1250001 to 2500000 issued on preferential basis pursuant to the Resolution Plan approved by Hon'ble NCLT Mumbai.**

Dear Sir/Madam,

We acknowledge the receipt of your application on the captioned matter, together with the enclosures and would advise that the Exchange is pleased to grant Listing approval to the listing application made by the company seeking permission for its aforesaid shares to be dealt in on the Exchange.

The Company should ensure compliance with the provisions of Regulation 167 of SEBI (ICDR) Regulations and as specified by SEBI from time to time.

Further, in case there is change exceeding two per cent of the total paid-up share capital of the Company, the Company shall file the shareholding pattern in XBRL mode as required under Regulations 31(1)(c) of SEBI LODR Regulations, 2015.

Please note that trading approval in the above-mentioned shares will be granted only after the company files with the Exchange:

- Listing approval from the National Stock Exchange of India Ltd. (if applicable) and
- Confirmation letters from NSDL/CDSL about crediting the above-mentioned shares to the respective beneficiary accounts/admitting the capital to the depository system. You are requested to file all such approvals together.
- Confirmation letters from NSDL/CDSL about lock-in of pre-preferential holding (if applicable).

In addition to above, the Company should note that as per Schedule XIX of ICDR Regulations and as specified by SEBI vide SEBI circular no. SEBI/HO/CFD/PoD-2/P/CIR/2023/00094 dated

June 21, 2023, "Listed entities shall make an application for trading approval to the stock exchange/s within seven working days from the date of grant of listing approval by the stock exchange/s" along with the documents specified by stock exchange/s from time to time. Any Non-compliance with the above requirement will attract fine as mentioned in SEBI Master circular no. SEBI/HO/CFD/PoD-2/P/CIR/2023/00094 dated June 21, 2023.

Yours faithfully,



**Marian Dsouza**  
**Assistant Vice President**



**Abhishek Kadlak**  
**Deputy Manager**